-+ 0.00%
-+ 0.00%
-+ 0.00%

Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318

Benzinga·09/28/2026 16:55:49
Listen to the news
Brookline Capital analyst Leah Rush initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $318.